Re-evaluation of treatment approach for mild and severe asthma
Invited conference paper presented and published in conference proceedings

香港中文大學研究人員

全文

其它資訊
摘要Asthma is a common disease affecting more than 300 million people worldwide. Despite the availability of effective treatments, real-life epidemiological studies showed that many asthmatics in different parts of the world are poorly controlled. This is likely due to a mismatch of treatment and the type of asthma the patients have. Despite the advances in our understanding of the underlying mechanisms of asthma and the improvement of asthma treatments, there are several major areas that still require more research efforts to improve the care and to prevent asthma. Asthma is a chronic inflammatory disease of the airway. However, we recommend as needed PRN bronchodilators as the first line treatment. When the severity increases, we recommend that patients should take regular anti-inflammatory treatment and should minimize the use bronchodilator. Many mild asthmatics continue to develop exacerbations and most exacerbations are precipitated by viral infections especially those related to human rhinovirus. Recent clinical trials using the PRN combination of bronchodilators and ICS appears to be a much better option for treating mild asthma. Another problem is the small percentage of severe asthma. We tend to use the same approach for all patients with severe asthma but they are likely to have different underlying mechanisms explaining their severity. Recent trials of using biologics have clearly demonstrated that only a small subgroup of asthma population will respond to a specific biologic. Immunotherapy has also been tested in many clinical trials. The problems of herterogeniety of the results, the difference in allergens used, the problem of muti-sensitizations make it difficult to use in the clinical settings. In order to improve the control of our asthmatics, we may need to rethink how we treat the mild asthma and how to determine the personalized treatments for the severe asthmatics.
著者Gary Wong
會議名稱30th Anniversary of Asia Pacific Association of Allergy, Asthma & Clinical Immunology (APAAACI)/2019 International Conference/2019 Annual Meeting of Chinese Society of Allergy (CSA)
會議開始日05.09.2019
會議完結日07.09.2019
會議地點Beijing
會議國家/地區中國
出版年份2019
月份9
語言英式英語

上次更新時間 2020-15-05 於 10:11